跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
ABRYSVO
Authorized
STANDARD
ABRYSVO
Pfizer Canada Ulc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
4118a6d093c57ee2
Company
Pfizer Canada Ulc
Type
Standard
Approval Details
Approval Id
4118a6d093c57ee2
Drug Approval Canada Name
ABRYSVO
Product Name
ABRYSVO
Status
Marketed
Status Date
2024-05-22
Original Market Date
2024-05-22
Din
02544040
Drug Class
Human
Dosage Form
Powder For Solution , Kit
Route Of Administration
Intramuscular
Schedule
Schedule D
Ahfs
80:12.00
Atc Original
J07BX05 RESPIRATORY SYNCYTIAL VIRUS VACCINE
Atc Name
j 07 bx 05
Aig Number
0265562001
Company Name
Pfizer Canada Ulc
Company Address
17300 Trans-Canada Highway, Kirkland, Quebec, Canada, H9J 2M5
Company Detail Path
/organization/pfizer-canada-ulc
Company Information
Pharmaceutical Company Name
Pfizer Canada Ulc
Country Name
Canada
Province Name
Quebec
City Name
kirkland,quebec,country_ca
Address
17300 rte Transcanadienne
Active Ingredients
RSV SUBGROUP B STABILIZED PREFUSION F PROTEIN
60 MCG / 0.5 ML
RSV SUBGROUP A STABILIZED PREFUSION F PROTEIN
60 MCG / 0.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
4118a6d093c57ee2
Type
Standard
Back to Health Canada Approvals
ABRYSVO - Health Canada Drug Approval Details